Leállítva2. fázis
This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).
A legfontosabb adatok
- Ki végzi
- AnaptysBio, Inc.
- Hol
- Anaheim, Ann Arbor, Atlanta, Auburn Hills, Baton Rouge, Baytown, Boise, Cerritos, Charlotte, Clarksville, Dallas, Detroit, Doral, Flossmoor, Fountain Valley, Fremont, Frisco, Hazelwood, Katy, Lancaster, Las Vegas, Lomita, Mason, Merrillville, Methuen, Miami, Nashville, New Albany, Oxnard, Pasadena, Philadelphia, Portland, Saint Joseph, San Antonio, Santa Monica, Spokane, Troy és Wilmington (Egyesült Államok)Mind a 41 helyszín megnézéseMég 6 másik országban, 37 helyszínen
- Azonosító
- Állapot
- Leállítva
- Fázis
- 2. fázis
- Résztvevők
- 201 fő vett részt
- Kezdés
- 2023. jún. 13.
- Befejezés
- 2025. jan. 7.
- A vizsgálat típusa
- Beavatkozással járó, 4 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- ANB032
- Placebo
- A regiszteradat frissítve
- 2025. február 14.
- Miért állt le
- ANB032 did not meet the primary endpoint in moderate-to-severe atopic dermatitis
Ki vehet részt
- Életkor
- 18 év – 65 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 10 feltétel megnézéseKevesebb
Ki vehet részt
- Male or female aged 18 to 65 years and in good general health
- Moderate to severe AD for at least 6 months prior to Randomization
- History of inadequate response to treatment for AD with topical medications or for whom topical treatments are otherwise medically inadvisable
- EASI score ≥ 16 at Screening and at Randomization
- vIGA AD score ≥ 3 at Screening and at Randomization
- AD involved BSA ≥ 10% at Screening and at Randomization
Ki nem vehet részt
- Not able to tolerate SC drug administration
- Tanning booth use or extended sun exposure that could affect disease severity or interfere with disease assessments within 4 weeks before Randomization
- Any factors that in the Investigator's opinion would predispose the subject to develop an infection
- Known or suspected congenital or acquired immunodeficiency state, or condition that would compromise the subject's immune status
Helyszínek itt: Egyesült Államok
Még 6 másik országban, 37 helyszínen
- Anaheim, CaliforniaHospital not named in the registry
- Ann Arbor, MichiganHospital not named in the registry
- Atlanta, GeorgiaHospital not named in the registry
- Auburn Hills, MichiganHospital not named in the registry
- Baton Rouge, LouisianaHospital not named in the registry
- Baytown, TexasHospital not named in the registry
- Boise, IdahoHospital not named in the registry
- Cerritos, CaliforniaHospital not named in the registry
- Charlotte, North CarolinaHospital not named in the registry
- Clarksville, IndianaHospital not named in the registry
- Dallas, TexasHospital not named in the registry
- Detroit, MichiganHospital not named in the registry
- Doral, FloridaHospital not named in the registry
- Flossmoor, IllinoisHospital not named in the registry
- Fountain Valley, CaliforniaHospital not named in the registry
- Fremont, CaliforniaHospital not named in the registry
- Frisco, TexasHospital not named in the registry
- Hazelwood, MissouriHospital not named in the registry
- Katy, TexasHospital not named in the registry
- Lancaster, CaliforniaHospital not named in the registry
- Las Vegas, NevadaHospital not named in the registry
- AnaptysBio Investigative 10-125Lomita, Egyesült Államok
- Mason, OhioHospital not named in the registry
- Merrillville, IndianaHospital not named in the registry
- Methuen, MassachusettsHospital not named in the registry
- Miami, FloridaHospital not named in the registry
- Miami, FloridaHospital not named in the registry
- Miami, FloridaHospital not named in the registry
- Miami, FloridaHospital not named in the registry
- Nashville, TennesseeHospital not named in the registry
- New Albany, IndianaHospital not named in the registry
- Oxnard, CaliforniaHospital not named in the registry
- Pasadena, CaliforniaHospital not named in the registry
- Philadelphia, PennsylvaniaHospital not named in the registry
- Portland, OregonHospital not named in the registry
- Saint Joseph, MissouriHospital not named in the registry
- San Antonio, TexasHospital not named in the registry
- Santa Monica, CaliforniaHospital not named in the registry
- Spokane, WashingtonHospital not named in the registry
- Troy, MichiganHospital not named in the registry
- Wilmington, North CarolinaHospital not named in the registry
A vizsgálatról
Mit akar kideríteni a vizsgálat
This study will evaluate the safety, tolerability, and efficacy of ANB032 in subjects with moderate to severe atopic dermatitis (AD).
A vizsgálat 4 csoportja
- ANB032 SC Dose 1A vizsgált kezelés
This arm will receive treatment SC
Kezelés: ANB032
- ANB032 SC Dose 2A vizsgált kezelés
This arm will receive treatment SC
Kezelés: ANB032
- ANB032 SC Dose 3A vizsgált kezelés
This arm will receive treatment SC
Kezelés: ANB032
- PlaceboPlacebo, összehasonlításként
This arm will receive Placebo SC
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of ANB032 in the Treatment of Subjects with Moderate to Severe Atopic Dermatitis
- A regiszteradat frissítve
- 2025. február 14.